Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours.

导出 OA

翻译打印收藏纠错

作者： Panagiotis A,Konstantinopoulos ^[1] ; Su-Chun,Cheng ^[2] ; Jeffrey G,Supko ^[3] ; Madeline,Polak ^[2] ; Andrea E,Wahner-Hendrickson ^[4] ; S Percy,Ivy ^[5] ; Brittany,Bowes ^[2] ; Hannah,Sawyer ^[2] ; Patrice,Basada ^[2] ; Martin,Hayes ^[2] ; Jennifer,Curtis ^[2] ; Neil,Horowitz ^[2] ; Alexi A,Wright ^[2] ; Susana M,Campos ^[2] ; Elena V,Ivanova ^[2] ; Cloud P,Paweletz ^[2] ; Sangeetha,Palakurthi ^[2] ; Joyce F,Liu ^[2] ; Alan D,D'Andrea ^[2] ; Prafulla C,Gokhale ^[2] ; Dipanjan,Chowdhury ^[2] ; Ursula A,Matulonis ^[2] ; Geoffrey I,Shapiro ^[2]

作者单位： Dana-Farber Cancer Institute, Boston, MA, USA. panagiotis_konstantinopoulos@dfci.harvard.edu. ^[1] Dana-Farber Cancer Institute, Boston, MA, USA. ^[2] Massachusetts General Hospital, Boston, MA, USA. ^[3] Mayo Clinic, Rochester, MN, USA. ^[4] National Cancer Institute, Bethesda, MD, USA. ^[5]

主题词抗肿瘤药(Antineoplastic Agents);HSP90热休克蛋白质类(HSP90 Heat-Shock Proteins);人类(Humans);卵巢肿瘤(Ovarian Neoplasms);酞嗪类(Phthalazines)

DOI 10.1038/s41416-021-01664-8

PMID 34887522

发布时间 2023-12-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交